It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Extracellular histones in neutrophil extracellular traps (NETs) or in chromatin from injured tissues are highly pathological, particularly when liberated by DNases. We report the development of small polyanions (SPAs) (~0.9–1.4 kDa) that interact electrostatically with histones, neutralizing their pathological effects. In vitro, SPAs inhibited the cytotoxic, platelet-activating and erythrocyte-damaging effects of histones, mechanistic studies revealing that SPAs block disruption of lipid-bilayers by histones. In vivo, SPAs significantly inhibited sepsis, deep-vein thrombosis, and cardiac and tissue-flap models of ischemia-reperfusion injury (IRI), but appeared to differ in their capacity to neutralize NET-bound versus free histones. Analysis of sera from sepsis and cardiac IRI patients supported these differential findings. Further investigations revealed this effect was likely due to the ability of certain SPAs to displace histones from NETs, thus destabilising the structure. Finally, based on our work, a non-toxic SPA that inhibits both NET-bound and free histone mediated pathologies was identified for clinical development.
Histones, proteins that bind DNA, are toxic for pathogens outside cells but can also cause multi-organ damage as seen in sepsis. Here the authors develop small negatively charged molecules that can be used as histone antidotes, and show that they improve the phenotype in mouse models with histone-related pathologies.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details









1 The Australian National University, ACRF Department of Cancer Biology and Therapeutics, The John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
2 Griffith University, Institute for Glycomics, Gold Coast, Australia (GRID:grid.1022.1) (ISNI:0000 0004 0437 5432)
3 Australian National University, Eccles Institute of Neuroscience, John Curtin School of Medical Research, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)
4 Illawarra Health and Medical Research Institute, Wollongong, Australia (GRID:grid.1001.0)
5 The Canberra Hospital, Intensive Care Unit, Canberra, Australia (GRID:grid.413314.0) (ISNI:0000 0000 9984 5644)
6 University of New South Wales, Vascular Biology and Translational Research, School of Medical Sciences, Sydney, Australia (GRID:grid.1005.4) (ISNI:0000 0004 4902 0432)
7 The Australian National University, Department of Applied Mathematics, Research School of Physics and Engineering, Canberra, Australia (GRID:grid.1001.0) (ISNI:0000 0001 2180 7477)